George Goldsmith, CEO of MED psilocybin company Compass Pathways “insists that he’s not in the psychedelics business.”
Business Insider (Paywall)
- Firstly, the compound they’re using is synthetic, not made from mushrooms.
- He anticipates psychedelic therapies to be on the market by 2025 and predicts a “cambrian explosion of innovation” in the space.
- The company, which has backers including Silicon Valley magnate Peter Thiel, recently went public and is now valued at around $1.2B.
